The classification of pneumonia is increasingly complex as the patient population becomes more diverse. More and more patients are identified with pneumonia attributed to multidrug-resistant (MDR) bacteria, occurring both in the hospital setting and outside of the hospital. This is likely related to the expanding pool of patients at risk for colonization with MDR bacteria. These expanding patient populations include individuals residing in nonhospital health care facilities (e.g., long-term nursing facilities, assisted living environments, rehabilitation centers), patients undergoing outpatient procedures or therapies (hemodialysis, wound care, infusion therapy), patients who have been recently discharged from the hospital setting, and those with significant underlying immunosuppression. Patients exposed to these nonhospital risks who develop pneumonia have traditionally been categorized as having community-acquired pneumonia (CAP). However, the new designation for pneumonia acquired in these environments is healthcare-associated pneumonia (HCAP). Additionally, some authors have categorized patients in nursing homes as developing nursing home-acquired pneumonia (NHAP) because there may be distinct epidemiological associations with this infection. Although HCAP is currently treated with the same protocols as CAP in many hospitals, recent evidence indicates that HCAP differs from CAP with respect to pathogens and prognosis, and in fact, more closely resembles hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) requiring broader empirical antimicrobial therapy than CAP.
largest single category of pneumonia patients. [2] [3] [4] [5] [6] In general, patients who develop HCAP are more similar to hospitalized patients than true community patients in that they have a greater burden of comorbidities, including cancer, chronic kidney disease, heart disease, chronic obstructive lung disease, immunosuppression, dementia, and impaired mobility. 2, 7, 8 DISTINGUISHING HCAP FROM CAP An important distinction of HCAP is that the pathogens are often MDR bacteria. 2 Therefore, the initial treatment of HCAP should be similar to that of HAP and VAP, which also differentiates it from CAP. 3, 4 Recognition of HCAP is particularly important for clinicians working in first-response areas such as emergency departments (EDs) so that appropriate initial antimicrobial therapy is not delayed. Several studies have demonstrated that delaying the delivery of appropriate antimicrobial therapy in patients with HAP, VAP, and HCAP results in excess mortality. [9] [10] [11] [12] Thus it is essential for physicians working in the ED to distinguish between HCAP and CAP to correctly assess and manage suspected cases of pneumonia. This therapeutic approach to HCAP also applies to other healthcare-associated infections where the pathogens are more similar to hospital-acquired organisms than to community-acquired ones. 7, 13 In defining healthcare-associated pneumonia (HCAP) as a distinct clinical entity, the most recent American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) nosocomial pneumonia guidelines defined a subset of patients at risk for harboring MDR organisms despite their residence in the community (Table 2) . 3 Although the ATS-IDSA guidelines were intended to be applied only to HCAP patients evaluated in the hospital setting, it is apparent these concepts are being extrapolated to nonhospitalized HCAP patients as well.
14 However, these criteria have never been prospectively validated and may not include all patients at risk for infection with MDR pathogens (e.g., do not include health care workers). Additionally, it is not clear whether this definition should be applied to patients who remain in a nonhospital environment, such as a nursing home or long-term care facility.
Several other definitions of HCAP are stated or implied in the medical literature. One prevalent use of the term, considered irrelevant to this discussion, is the use of health care-associated as a replacement for, or synonym of, nosocomial or hospital-associated. 15 A second use of the term is hospitalized with community-acquired pneumonia, which also fails to capture the concept presented in the ATS-IDSA guidelines. 16 The key issue is to define HCAP separately from CAP because the pathogens associated with HCAP more closely resemble those seen with HAP and VAP. More importantly, the initial antibiotic treatment of patients with HCAP should differ from that employed for patients with CAP. 3, 17 CLINICAL STUDIES OF HCAP Kollef et al reviewed a large multicenter database of 4543 patients with culture-positive pneumonia and identified 20% as having HCAP. 2 In this retrospective cohort analysis of a multiinstitutional database, cases of culture-positive pneumonia were identified by the international classification of diseases (ICD)-9 codes. Patients were then stratified as having CAP (49%), HCAP (22%), HAP (18%), or VAP (11%). The most common pathogens in HCAP were methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (26.5% and 25.3%, respectively). Conversely, Streptococcus pneumoniae and Haemophilus species were seen more frequently in CAP (16.6% and 16.6%) than in HCAP (3.1% and 5.8%). The mortality rates of HCAP patients and HAP patients were similar (19.8% and 18.8%, respectively) and were significantly higher than in CAP patients (10.0%). However, limitations of this study included the use of only hospitalized patient data, inclusion of only patients with early-onset pneumonia, misclassification bias, and the exclusion of culturenegative patients. The very high rates of Pseudomonas aeruginosa (17.1%) and MRSA (8.9%) as causative pathogens in CAP patients also suggest that misclassification occurred; patients with HCAP were likely misclassified as CAP in this database study.
Two additional studies assessed the risk factors for colonization and infection with MDR organisms in hospitalized patients, many of whom did not have pneumonia. The first of these studies assessed variables associated with MDR gram-negative bacillus carriage. 18 In this prospective, case-control study it was found that predictors of MDR gram-negative bacillus colonization included several subsets of patients also included in the new ATS-IDSA definition of HCAP: long-term care facility residents, hemodialysis patients, and patients who have recently received antibiotic therapy. Similarly, a prospective surveillance study of MRSA showed that patients meeting HCAP criteria (recent hospitalization, long-term care residents, dialysis patients, or home nursing care) accounted for 99% of ''communityacquired'' MRSA cases. 19 Another manuscript assessed the occurrence of culture-positive CAP and HCAP at a single center admitted between January 1, 2003, and December 31, 2005. 12 The main objective of this study was to characterize the incidence, microbiology, and treatment patterns for CAP and HCAP among patients requiring hospital admission. Among the 639 patients hospitalized with pneumonia, HCAP was more common than CAP (67.4% vs 32.6%). The most common pathogens identified overall included MRSA (24.6%), Streptococcus pneumoniae (20.3%), Pseudomonas aeruginosa (18.8%), methicillin-sensitive Staphylococcus aureus (13.8%), and Haemophilus influenzae (8.5%). Patients with HCAP were statistically more likely to be infected with MRSA, Pseudomonas aeruginosa, and other gram-negative bacilli compared with patients with CAP. Hospital mortality was found to be statistically greater among patients with HCAP compared with CAP (24.6% vs 9.1%; p < 0.001). Moreover, initial administration of inappropriate antimicrobial treatment was statistically more common among HCAP patients (28.3% vs 13.0%; p < 0.001) and was identified as an independent risk factor for hospital mortality (Fig. 1) .
These clinical studies performed in the United States suggest that HCAP is a common category of pneumonia requiring hospitalization and that the pathogens causing HCAP are most commonly MDR gramnegative bacilli and MRSA. They also point out that patients with HCAP have more comorbidities and are more likely to receive inappropriate antibiotic treatment compared with patients with CAP. This combination is worrisome because patients with HCAP would appear to be potentially more vulnerable to lapses or delays in appropriate antimicrobial administration. This action has led to the exclusion of HCAP patients from studies of adherence to antibiotic therapy recommendations for patients with CAP. Fujitani and Yu considered HCAP ''a good idea'' but noted ''problems with its execution.'' 20 They noted that the definitions of HAP, CAP, and HCAP have varied among different large-scale studies and suggest that ''classification schemes are inherently imprecise because patient groups overlap in the HCAP categories.'' Wunderink also noted that ''a distinction between HCAP and CAP has never been totally clear.'' 21 He concluded, however, by stating that ''despite these issues, the use of the HCAP category Figure 1 Comparison of mortality in patients with CAP and HCAP. CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia.
ACCEPTANCE OF HCAP AS
THE ALPHABET SOUP OF PNEUMONIA: CAP, HAP, HCAP, NHAP, AND VAP/ANAND, KOLLEF has led to more appropriate antibiotic therapy for the majority of patients and clearly assisted decision making.'' 21 A recent international forum on respiratory tract infections also highlighted the need to better define HCAP as a distinct entity. 22 In this paper, two different categories of HCAP were described based on the presence of two of the three following risk factors: (1) severe pneumonia requiring mechanical ventilation; (2) prior antibiotics for more than 3 days within the past 6 months; or (3) poor functional status as defined as an activity of daily living (ADL) score of > 12.5. The different categorizations of HCAP were presumably associated with different risks of infection with MDR bacteria.
HCAP OUTSIDE OF THE UNITED STATES
Two studies have examined HCAP as a distinct entity in Barcelona, Spain. The first study was done between 1997 and 1998. 23 These authors evaluated 559 hospitalized patients with CAP, of which 60 (11%) had infection caused by gram-negative bacilli, and 39 (65%) of these were Pseudomonas aeruginosa. Patients infected with gram-negative bacilli were more likely to have clinical criteria consistent with HCAP, including probable aspiration, previous hospitalization, previous antimicrobial treatment, and the presence of pulmonary comorbidities. CAP due to gram-negative bacilli was associated with a significantly greater mortality. This appeared to be associated with the greater administration of inappropriate initial antimicrobial treatment in patients with CAP due to Pseudomonas aeruginosa. A more recent study from Barcelona examined 727 hospitalized patients with pneumonia of which 126 (17.3%) were HCAP. 24 Similar to the U.S. experience, 2,12 HCAP patients were older, had greater comorbidities, and were commonly classified into highrisk pneumonia severity index classes compared with patients with CAP. However, unlike the U.S. experience, Streptococcus pneumoniae was found to be the most common cause of CAP and HCAP. Like the U.S. experience, HCAP patients were more likely to be infected with Staphylococcus aureus and gram-negative bacilli and were more likely to receive inappropriate initial antimicrobial treatment. These studies support the more global recognition of HCAP as a distinct pneumonia category.
IS NHAP DIFFERENT FROM HCAP?
The degree to which the HCAP definition applies to patients with pneumonia who remain in nonhospital health care settings, such as nursing homes, is not clear. Mortality rates in NHAP are higher than those for CAP, 2, 25, 26 but controlling for different factors that affect this risk is difficult. For example, in a review by El Solh et al of 88 patients with culture-confirmed cases of severe NHAP, previous use of antibiotics (a component of the ATS-IDSA definition) was found to be predictive of drug-resistant bacteria. 27 However, the other predictor of drug resistance in this study was an ADL score 12.5, a feature not considered in the ATS-IDSA definition of HCAP. Likewise, at least one study suggests the risk of MDR bacteria is no higher for NHAP than for CAP, although the NHAP patients had a greater mortality related to poor functional status. 25 A prospective case-control study comparing NHAP patients and age-matched CAP patients showed the presentation of pneumonia was strikingly different between groups. 26 Compared with CAP patients, NHAP patients were less likely to have a productive cough (61% vs 35%), chills (58% vs 24%), headache (32% vs 5%), sore throat (19% vs 7%), myalgia (33% vs 7%), or arthralgia (10% vs 0%). Although reported as being statistically nonsignificant, NHAP patients were almost twice as likely to have confusion (70% vs 37%). NHAP patients were also more likely to die in hospital (32% vs 14%).
An article reviewing 18 primary studies published between 1978 and 1994 evaluated the etiology of pneumonia in residents of long-term care facilities. 28 In this study, the most common pathogens were gramnegative bacilli (18%), Streptococcus pneumoniae (16%), Haemophilus influenza (11%), and Staphylococcus aureus (6%). Mycoplasma, Chlamydia, and Legionella accounted for < 1% of cases, and 29% of cases did not have an identifiable pathogen. The primary studies showed marked variability in the frequency of causative pathogens: Gram-negative bacilli isolation varied from 0 to 55% across studies; Streptococcus pneumoniae ranged from 0 to 39%; Staphylococcus aureus was 0 to 33%; and Legionella varied from 0 to 6%. The primary studies' evaluation of the causative pathogens was widely discrepant. Some had no microbiological criteria, others required a high-quality sputum specimen, and some allowed positive blood cultures to suffice if sputum was negative. None of the studies rigorously pursued the isolation of atypical organisms. However, the high incidence of infection due to gram-negative bacilli and Staphylococcus aureus supports the premise that NHAP should be included in the category of HCAP.
IS SEVERE CAP DIFFERENT FROM HCAP?
A growing consensus supports the assertion that the clinical features of HCAP are different from CAP, including severe CAP. 29 There are many definitions of severe CAP, and several scoring systems have been used for assessing CAP severity and the need for hospital admission or intensive care. [30] [31] [32] [33] Patients with severe CAP or HCAP may need intensive care or mechanical ventilation or may have pneumonia complicated by sepsis, shock, bacteremia, or multiple organ failure.
Severe CAP may be caused by several pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and anaerobic bacteria that typically are not MDR strains. 34 Even CAP caused by Staphylococcus aureus or gram-negative bacteria, such as Klebsiella pneumoniae, is usually not MDR if the patient has not had prior antibiotics or close contact with the health care system. Atypical pathogens such as Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumonia are common in the United States. Coinfection with these bacteria occurs, and in contrast to HCAP, the pathogens are not MDR or necessarily associated with prior antibiotic use or contact with the health care system. In addition, although CAP is more likely to be caused by bacteria, viruses are also important causes of CAP (influenza virus, respiratory syncytial virus, adenovirus). Patient risk factors for severe CAP include underlying medical diseases, such as chronic lung disease, exposure to animals, risk of aspiration, exposure to other infected persons, or seasonal epidemics. Additionally, severe CAP has now been associated with pathogens typically causing HCAP/HAP/VAP in the past, further blurring these distinctions in some circumstances, including MRSA and Acinetobacter species. 35, 36 In a review of severe CAP by Ewig and Torres, microbial patterns in Barcelona, Spain, Lille, France, and South Africa were examined. Streptococcus pneumoniae rates were 15%, 27%, and 29%, respectively; Klebsiella pneumoniae was 2%, 2%, and 19%, respectively; and Staphylococcus aureus was 0%, 19%, and 3%, respectively. 34 A review of etiology identified in 16 studies of severe CAP found Streptococcus pneumoniae ranged from 12 to 38%, Haemophilus influenzae from 0 to 13%, enteric gram-negative bacilli from 0 to 34%, Staphylococcus species from 0 to 15%, Pseudomonas aeruginosa from 0 to 5%, and Legionella pneumophila from 0 to 30%. Unfortunately, these differences represent the diversity of patient populations studied and different time periods but do not address MDR pathogens. The study includes some patients who would now be classified as HCAP due to risk for infection with MDR pathogens. A later study by Rello et al in Barcelona, Spain, compared the microbiology of 106 severe CAP patients requiring mechanical ventilation with 98 CAP patients who were not ventilated. 37 Microbiological diagnosis was made in 57.3% of patients, and the most common bacterial pathogens were Streptococcus pneumoniae, Legionella pneumophila, and Haemophilus influenzae. Pseudomonas aeruginosa (6.6% vs 1.0%), and Legionella pneumoniae infections (15.1% vs 7.1%) were higher in intubated vs nonintubated patients. Overall mortality was 44.3% in intubated patients versus 23.5% overall. Of note, bacteriologic investigation led to changes in antibiotic therapy in 41.6% of patients, including 11 patients (5%) in whom initial treatment was ineffective.
IMPLICATIONS FOR TREATMENT
The issue of appropriate antibiotic therapy for HCAP revolves around the microbial etiology of HCAP, specifically whether broad-spectrum antibiotic therapy is needed to empirically cover MDR pathogens such as Pseudomonas aeruginosa, MRSA, and extended-blactamase-producing Enterobacteriaceae. The findings from the available epidemiological studies conducted in the United States support treating MDR pathogens in patients with HCAP risk factors. 2, 12 However, there are differences with the two European studies in terms of etiology. 23, 24 A report of gram-negative pneumonias from a prospective CAP database demonstrated that most patients with gram-negative CAP had risk factors that would likely qualify them for HCAP. 38 Provision of appropriate initial therapy was associated with improvement in mortality, but the difference was not statistically significant (32% vs 13%, p ¼ 0.27).
Even if MDR pathogens occur in high frequency, use of broad-spectrum therapy is still of unclear benefit for mortality in patients with HCAP. Two studies, both using the before-after intervention format, specifically addressed this issue for VAP and HAP. Ibrahim et al found that a three-drug, broad-spectrum protocol for late-onset VAP decreased the administration of inappropriate initial empirical antibiotic therapy to 5.8% as opposed to 52% prior to protocol introduction. 39 Mortality was unaffected, although the incidence of recurrent VAP and subsequent infection with MDR pathogens decreased. The second study, which used a similar type of empirical protocol, also demonstrated that inappropriate initial antibiotic therapy was decreased significantly with the use of broader-spectrum therapy and resulted in decreased mortality (27% vs 8%, p ¼ 0.03) at 14 days. 40 However, the statistically significant mortality benefit was not maintained for 30-day or hospital mortality.
CONCLUSIONS
It is intuitively logical that broader antimicrobial coverage should benefit patients with HCAP due to the MDR bacteria associated with this infection. Additional epidemiological studies are needed to identify patients with HCAP infected with MDR pathogens. Additionally, interventional studies should be performed to assess the clinical impact of broad-spectrum antimicrobial treatment of patients with HCAP. Until such studies are performed clinicians should be aware of local risk factors for pneumonia caused by MDR bacteria. 
